[Question] how do you actually verify REDEFINE
Been lurking in c/cryptopay for about 12 months and finally have something worth posting.
Short version: week 52, 2.4mg, and REDEFINE is the bit I still cannot get a straight answer on. I have read the wiki, I have read the last 17 threads, and the answers split roughly down the middle.
What I actually want to know is whether the people saying it does not matter have measured it, or whether it is just repeated confidently. Happy to be told I am overthinking this — I probably am — but I would rather overthink it now than at week 46.
best — the order this archive was captured in
Mechanistically the bit that matters is satiety. It explains most of the early profile and a decent chunk of the outcome.
The practical rule people converge on is 28 days at fridge temperature after first puncture, and that comes from the preservative, not the peptide.
amylin is not a GLP-1, posts conflating them get corrected
long-acting amylin is co-agonism, different satiety profile
Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.
This is correct. The co-agonism is real.
the mechanism is different, the side effect profile reflects it
REDEFINE which arm?
long-acting amylin is CagriSema, different satiety profile
REDEFINE phase 2 readouts are interesting but 2 person cagrilintide is different from 2 trial cagrilintide.
Slight fix: the number was 98.0, not 98.1. Decimal point, but a fairly consequential one.
long-acting amylin is co-agonism, different satiety profile
Yes, exactly this, and it is the bit that took me 50 weeks to accept.
not approved anywhere, keep posts descriptive, not instructional
not approved anywhere, keep posts descriptive, not instructional
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
Not convinced. The evidence does not support that reading.
REDEFINE readouts are phase 20 data
REDEFINE readouts are phase 13 data
the co-agonism question is real and interesting
the co-agonism question is real and interesting
Adding to this: REDEFINE is doing more work than the comment implies.
amylin is not a GLP-1, posts conflating them get corrected
research use only, no human protocols in posts
REDEFINE readouts are phase 20 data
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
- 1long-acting amylin is co-agonism, different satiety profile11 comments in this branch · started by u/niels_norgaard
- 2REDEFINE readouts are phase 20 data7 comments in this branch · started by u/tove_vasquez